- 27 September
-
On September 26, 2024, TASS hosted an expert discussion in the format of a federal teleconference Moscow-St. Petersburg-Ekaterinburg-Novosibirsk-Vologda-Anapa, dedicated to discussing the role, reasons and mechanisms for stimulating In Ekaterinburg, Alexander Petrov, the Chairman of the Board of Directors of Medsintez Plant LLC, told the participants about Triazavirin, an innovative domestic antiviral drug, as a success case of private investment in science.
- 07 September
-
60 leading Russian reproductologists visited the pharmaceutical company Medsintez Plant in Novouralsk on September 4, 2024. This event was timed to coincide with the celebration of the 3rd anniversary of the opening of the production workshop for biotechnological substances for the reproductive health of women, as well as the Annual International Conference «Reproductive Technologies Today and Tomorrow» in Ekaterinburg. Leading experts and conference speakers visited the production of the first Russian follitropin alpha for the treatment of human infertility, Primapur®.
- 02 August
-
In 2024, the Medsintez Plant in collaboration with Tonghua Anrate Biopharmaceutical Co. launched the production of the substance and finished dosage forms of the world's first registered drug of recombinant human albumin. The drug was obtained using Pichia Pastoris cells by the recombinant DNA technology.
- 11 July
-
The Medsintez Plant has participated in an international business meeting with the delegation from the United Arab Emirates as part of the INNOPROM 2024 business program in Ekaterinburg. The meeting with representatives of the national Ministry of Industry, pharmaceutical and medical industries of the UAE was organized by the Ministry of Industry and Trade of the Russian Federation. The meeting was attended by the Deputy Minister of Industry and Advanced Technology of the UAE, representatives of Globalpharma, SayGen, Hayat Biotech, Abu Dhabi Medical Devices.
Nonprofit Partnership "Ural Biomedical Cluster" was founded in December 2010 as a comprehensive innovative project. Its difference from an industrial cluster is that, in addition to manufacturing facilities, there are research centers, laboratories for preclinical studies, educational structures and clinics successfully operating based on the Cluster.
Strategic goal of the Ural Biomedical Cluster is to form a high-tech complex of interconnected production and infrastructure facilities for development, production and sale of modern medicines, medical equipment and high- quality medical devices in the Urals region.
The global mission of the Ural Biomedical Cluster is a widespread increase in availability of advanced medical technologies in Russia.
Today, the Ural Biomedical Cluster includes over 30 companies.
Ural Biomedical Cluster Services:
Intellectual Property
Management Patent search, detection of patented technologies, patent landscape designing, intellectual property protection, legal support.
Project Management
Development and execution of a registration dossier, support, business planning, investor search, strategic planning.
Technology Transfer
Development and scaling of original formulations for pharmaceutical products and drugs, existing technologies transfer to a specific site (localization of production).
Human Resources
Personnel training upon request: master's degree, residency, advanced training courses, internships at the enterprises of the Cluster and partners.
Contract Manufacturing
Manufacturing of pharmaceutical products and medical devices to order.
Related Services
Provision of office, laboratory and production premises, logistics services.
Articles of Association dated 24/9/2012
